CDK9 and acute myeloid leukemia: In vitro and in vivo antitumor activity of dinaciclib in mixed lineage leukemia fusion protein AML, regarded as a chemotherapy resistant and poor-prognosis subtype, lends further support to the functionality and therapeutic effects of the anti-CDK9 properties of dinaciclib (168).